MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease type 2A

Agostinho G. Rocha, Antonietta Franco, Andrzej M. Krezel, Jeanne M. Rumsey, Justin M. Alberti, William C. Knight, Nikolaos Biris, Emmanouil Zacharioudakis, James W. Janetka, Robert H. Baloh, Richard N. Kitsis, Daria Mochly-Rosen, R. Reid Townsend, Evripidis Gavathiotis, Gerald W. Dorn

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Mitofusins (MFNs) promote fusion-mediated mitochondrial content exchange and subcellular trafficking. Mutations in Mfn2 cause neurodegenerative Charcot-Marie-Tooth disease type 2A (CMT2A).We showed that MFN2 activity can be determined by Met376 and His380 interactions with Asp725 and Leu727 and controlled by PINK1 kinase-mediated phosphorylation of adjacent MFN2 Ser378. Small-molecule mimics of the peptide-peptide interface of MFN2 disrupted this interaction, allosterically activating MFN2 and promoting mitochondrial fusion. These first-in-class mitofusin agonists overcame dominant mitochondrial defects provoked in cultured neurons by CMT2A mutants MFN2 Arg94→Gln94 and MFN2 Thr105→Met105, as demonstrated by amelioration of mitochondrial dysmotility, fragmentation, depolarization, and clumping. A mitofusin agonist normalized axonal mitochondrial trafficking within sciatic nerves of MFN2 Thr105→Met105 mice, promising a therapeutic approach for CMT2A and other untreatable diseases of impaired neuronal mitochondrial dynamism and/or trafficking.

Original languageEnglish (US)
Pages (from-to)336-341
Number of pages6
JournalScience
Volume360
Issue number6386
DOIs
StatePublished - Apr 20 2018

Fingerprint

Mitochondrial Dynamics
Peptides
Sciatic Nerve
Phosphotransferases
Phosphorylation
Neurons
Mutation
Type 2A Charcot-Marie-Tooth disease
Therapeutics

ASJC Scopus subject areas

  • General

Cite this

Rocha, A. G., Franco, A., Krezel, A. M., Rumsey, J. M., Alberti, J. M., Knight, W. C., ... Dorn, G. W. (2018). MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease type 2A. Science, 360(6386), 336-341. https://doi.org/10.1126/science.aao1785

MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease type 2A. / Rocha, Agostinho G.; Franco, Antonietta; Krezel, Andrzej M.; Rumsey, Jeanne M.; Alberti, Justin M.; Knight, William C.; Biris, Nikolaos; Zacharioudakis, Emmanouil; Janetka, James W.; Baloh, Robert H.; Kitsis, Richard N.; Mochly-Rosen, Daria; Townsend, R. Reid; Gavathiotis, Evripidis; Dorn, Gerald W.

In: Science, Vol. 360, No. 6386, 20.04.2018, p. 336-341.

Research output: Contribution to journalArticle

Rocha, AG, Franco, A, Krezel, AM, Rumsey, JM, Alberti, JM, Knight, WC, Biris, N, Zacharioudakis, E, Janetka, JW, Baloh, RH, Kitsis, RN, Mochly-Rosen, D, Townsend, RR, Gavathiotis, E & Dorn, GW 2018, 'MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease type 2A', Science, vol. 360, no. 6386, pp. 336-341. https://doi.org/10.1126/science.aao1785
Rocha AG, Franco A, Krezel AM, Rumsey JM, Alberti JM, Knight WC et al. MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease type 2A. Science. 2018 Apr 20;360(6386):336-341. https://doi.org/10.1126/science.aao1785
Rocha, Agostinho G. ; Franco, Antonietta ; Krezel, Andrzej M. ; Rumsey, Jeanne M. ; Alberti, Justin M. ; Knight, William C. ; Biris, Nikolaos ; Zacharioudakis, Emmanouil ; Janetka, James W. ; Baloh, Robert H. ; Kitsis, Richard N. ; Mochly-Rosen, Daria ; Townsend, R. Reid ; Gavathiotis, Evripidis ; Dorn, Gerald W. / MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease type 2A. In: Science. 2018 ; Vol. 360, No. 6386. pp. 336-341.
@article{b8cca630d6784035854655e97776fbc8,
title = "MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease type 2A",
abstract = "Mitofusins (MFNs) promote fusion-mediated mitochondrial content exchange and subcellular trafficking. Mutations in Mfn2 cause neurodegenerative Charcot-Marie-Tooth disease type 2A (CMT2A).We showed that MFN2 activity can be determined by Met376 and His380 interactions with Asp725 and Leu727 and controlled by PINK1 kinase-mediated phosphorylation of adjacent MFN2 Ser378. Small-molecule mimics of the peptide-peptide interface of MFN2 disrupted this interaction, allosterically activating MFN2 and promoting mitochondrial fusion. These first-in-class mitofusin agonists overcame dominant mitochondrial defects provoked in cultured neurons by CMT2A mutants MFN2 Arg94→Gln94 and MFN2 Thr105→Met105, as demonstrated by amelioration of mitochondrial dysmotility, fragmentation, depolarization, and clumping. A mitofusin agonist normalized axonal mitochondrial trafficking within sciatic nerves of MFN2 Thr105→Met105 mice, promising a therapeutic approach for CMT2A and other untreatable diseases of impaired neuronal mitochondrial dynamism and/or trafficking.",
author = "Rocha, {Agostinho G.} and Antonietta Franco and Krezel, {Andrzej M.} and Rumsey, {Jeanne M.} and Alberti, {Justin M.} and Knight, {William C.} and Nikolaos Biris and Emmanouil Zacharioudakis and Janetka, {James W.} and Baloh, {Robert H.} and Kitsis, {Richard N.} and Daria Mochly-Rosen and Townsend, {R. Reid} and Evripidis Gavathiotis and Dorn, {Gerald W.}",
year = "2018",
month = "4",
day = "20",
doi = "10.1126/science.aao1785",
language = "English (US)",
volume = "360",
pages = "336--341",
journal = "Science",
issn = "0036-8075",
publisher = "American Association for the Advancement of Science",
number = "6386",

}

TY - JOUR

T1 - MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease type 2A

AU - Rocha, Agostinho G.

AU - Franco, Antonietta

AU - Krezel, Andrzej M.

AU - Rumsey, Jeanne M.

AU - Alberti, Justin M.

AU - Knight, William C.

AU - Biris, Nikolaos

AU - Zacharioudakis, Emmanouil

AU - Janetka, James W.

AU - Baloh, Robert H.

AU - Kitsis, Richard N.

AU - Mochly-Rosen, Daria

AU - Townsend, R. Reid

AU - Gavathiotis, Evripidis

AU - Dorn, Gerald W.

PY - 2018/4/20

Y1 - 2018/4/20

N2 - Mitofusins (MFNs) promote fusion-mediated mitochondrial content exchange and subcellular trafficking. Mutations in Mfn2 cause neurodegenerative Charcot-Marie-Tooth disease type 2A (CMT2A).We showed that MFN2 activity can be determined by Met376 and His380 interactions with Asp725 and Leu727 and controlled by PINK1 kinase-mediated phosphorylation of adjacent MFN2 Ser378. Small-molecule mimics of the peptide-peptide interface of MFN2 disrupted this interaction, allosterically activating MFN2 and promoting mitochondrial fusion. These first-in-class mitofusin agonists overcame dominant mitochondrial defects provoked in cultured neurons by CMT2A mutants MFN2 Arg94→Gln94 and MFN2 Thr105→Met105, as demonstrated by amelioration of mitochondrial dysmotility, fragmentation, depolarization, and clumping. A mitofusin agonist normalized axonal mitochondrial trafficking within sciatic nerves of MFN2 Thr105→Met105 mice, promising a therapeutic approach for CMT2A and other untreatable diseases of impaired neuronal mitochondrial dynamism and/or trafficking.

AB - Mitofusins (MFNs) promote fusion-mediated mitochondrial content exchange and subcellular trafficking. Mutations in Mfn2 cause neurodegenerative Charcot-Marie-Tooth disease type 2A (CMT2A).We showed that MFN2 activity can be determined by Met376 and His380 interactions with Asp725 and Leu727 and controlled by PINK1 kinase-mediated phosphorylation of adjacent MFN2 Ser378. Small-molecule mimics of the peptide-peptide interface of MFN2 disrupted this interaction, allosterically activating MFN2 and promoting mitochondrial fusion. These first-in-class mitofusin agonists overcame dominant mitochondrial defects provoked in cultured neurons by CMT2A mutants MFN2 Arg94→Gln94 and MFN2 Thr105→Met105, as demonstrated by amelioration of mitochondrial dysmotility, fragmentation, depolarization, and clumping. A mitofusin agonist normalized axonal mitochondrial trafficking within sciatic nerves of MFN2 Thr105→Met105 mice, promising a therapeutic approach for CMT2A and other untreatable diseases of impaired neuronal mitochondrial dynamism and/or trafficking.

UR - http://www.scopus.com/inward/record.url?scp=85045684908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045684908&partnerID=8YFLogxK

U2 - 10.1126/science.aao1785

DO - 10.1126/science.aao1785

M3 - Article

VL - 360

SP - 336

EP - 341

JO - Science

JF - Science

SN - 0036-8075

IS - 6386

ER -